All In Biotech

Drug Trial Radar · NCT07921420

MF-300 for Treatment of Age-Related Sarcopenia

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MF-300 in Subjects With Age-related Sarcopenia

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jun 1, 2028

Study completion Sep 1, 2028

Sponsor

Lead sponsor
Epirium Bio Inc.Industry
Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2b clinical trial will evaluate whether MF-300 can improve physical function and muscle strength and assess its safety in adults aged 65 years and older with sarcopenia. The study will also evaluate how MF-300 is processed by the body and its effects on measures related to muscle health, quality of life, and physical activity. Participants will receive MF-300 or placebo once daily for 24 weeks. The study includes an initial open-label part evaluating MF-300 followed by a randomized, placebo-controlled part evaluating two dose levels of MF-300.

Conditions

  • Sarcopenia in Elderly

Interventions

  • MF-300Drug

    oral tablet at doses of 75mg

  • PlaceboDrug

    matching placebo oral tablet

  • MF-300Drug

    oral tablet at doses of 200 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-times chair stand test (5xCST)Time frame: Baseline, Week 12, and Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.